血清25(OH)D和骨转换标志物与老年髋部骨折的相关性分析

目的初步探讨血清25(OH)D和骨转换标志物在老年骨质疏松性髋部骨折预测中的价值。方法选取2015年5月至2016年4月就诊于我院的330例老年髋部骨折患者和331例非骨折患者分别作为骨折组和对照组纳入本研究,收集患者的一般临床资料如年龄、性别、身高、体重、体质量指数、吸烟史以及饮酒史,测定血清25(OH)D、1型前胶原氨基末端前肽(Nterminal extension propeptide of type-I collagen,P1NP)、骨钙素(osteocalcin,OC)、1型胶原交联羧基末端肽(C-terminal telopeptide of type-I collagen,CTX)和甲状旁腺激素(parathyroid hormone,PTH),并对其进行统计学分析。结果血清25(OH)D在骨折组明显低于对照组,并且骨折组患者年龄、血清P1NP、OC、CTX和PTH明显高于对照组(P0.05)。运用Pearson相关分析显示血清25(OH)D与PTH、P1NP、OC和CTX呈明显负相关(P0.05)。对差异显著的参数经多因素Logistic回归分析显示,年龄、性别、血清25(OH)D、CTX与PTH是骨折发生的独立危险因素(P0.05)。受试者工作特征(receiver operator curve,ROC)曲线分析结果显示,年龄、血清25(OH)D和CTX的曲线下面积值分别为0.819、0.802和0.666,对预测髋部骨折具有一定的意义。结论高龄、维生素D缺乏以及血清CTX水平升高提示发生老年髋部骨折的风险增高,对于此类患者应警惕髋部骨折的发生,提前采取措施进行预防。     

Vitamin D insufficiency defined by serum 25-hydroxyvitamin D and parathyroid hormone before and after oral vitamin D3 load in Japanese subjects

Vitamin D insufficiency is a risk for both skeletal and nonskeletal health. However, some ambiguity remains about threshold serum 25(OH)D for vitamin D insufficiency. To determine the threshold serum 25(OH)D to maintain normal calcium availability without elevation in serum parathyroid hormone (PTH) among Japanese subjects with various calcium intakes, we conducted a multicenter prospective open-labeled study. We recruited 107 ambulatory subjects without disorders affecting vitamin D metabolism to whom oral vitamin D₃ 800?IU/day for 4?weeks or 1,200?IU/day for 8?weeks was given. Serum 25(OH)D, PTH, calcium, phosphate, and magnesium were measured before and after vitamin D₃ supplementation. Calcium intake was assessed by questionnaires. When all the data were combined, serum 25(OH)D was negatively correlated with PTH. The cubic spline curve between serum 25(OH)D and PTH indicated PTH reached its plateau between 35 and 40?pg/ml at 25(OH)D between 25 and 30?ng/ml. Vitamin D₃ supplementation increased serum 25(OH)D and decreased PTH. Change in PTH correlated positively with baseline serum 25(OH)D. From the regression analyses, baseline serum 25(OH)D above 28?ng/ml corresponded to the threshold level without reduction in PTH after vitamin D₃ supplementation. In multivariate regression analyses, age but not calcium intake was a significant determinant of PTH. We concluded that a serum 25(OH)D level of 28?ng/ml was identified as a threshold for vitamin D insufficiency necessary to stabilize PTH to optimal levels.     

老年女性晒太阳与其血清25-羟基维生素D关系的调查

目的调查老年女性体内维生素D的含量情况,以及血清25-羟基维生素D[25(OH)D]与晒太阳的关系。方法调查243名老年女性平时晒太阳的情况,年龄61~93岁,平均(81±4)岁,并检测其血清25(OH)D水平,然后分析两者之间的关系。结果老年女性血清25(OH)D正常率仅为7.41%。在243名老年女性中,坚持晒太阳的有157名(64.61%),其25(OH)D含量为(16.81±9.61)ng/ml,不晒太阳的有86名(35.39%),其25(OH)D含量为(13.34±7.78)ng/ml,两者在25(OH)D含量上差异有统计学意义(P0.01)。结论老年女性维生素D正常率极低,而晒太阳是提高老年女性血清25(OH)D含量的重要手段。     

2型糖尿病患者血清25-经维生素D水平与骨密度的关系

目的 探讨2型糖尿病患者不同血清25-( OH) D水平与骨密度的关系。方法 选择住院的2型糖尿病患者288例,根据25-( OH) D水平对其进行分组：25-( OH) D>30ng/mL为维生素D充足组;20ng/mL <25-( OH ) D≤30 ng/mL为维生素D不足组;l0 ng/mL <25-( OH) D <20 ng/mL为维生素D缺乏组;25-( OH) D <10ng/mL为维生素D严重缺乏组。采用双能X线骨密度仪(DXA)测量受试者腰椎L1-4、股骨颈及全髓的骨密度。分析不同水平25-( OH ) D与骨密度的关系。结果 维生素D充足组、维生素D不足组、维生素D缺乏组、维生素D严重缺乏组的患者例数(所占比例)分别为10例(3. 5%) ,74例(25.7%) ,177例(61.5%) ,27例(9.3%)。不同性别组25-( OH ) D水平无明显差异,但是女性患者的腰椎L1-4、股骨颈、全髋的骨密度均较男性低。pearscm相关分析显示25-( OH) D水平与腰椎L1-4、股骨颈、全髓的骨密度均无相关性(分别为r=0.080 P=0.262;r=0. 139 P=0. 051;r=0.068 P=0. 342)。结论 2型糖尿病患者25-( OH) D水平与腰椎L1-4、股骨颈、全髓的骨密度均无明显相关性。     

Greater seasonal cycling of 25-hydroxyvitamin D is associated with increased parathyroid hormone and bone resorption

Summary

This analysis assessed whether seasonal change in 25-hydroxyvitamin D concentration was associated with bone resorption, as evidenced by serum parathyroid hormone and C-terminal telopeptide concentrations. The main finding was that increased seasonal fluctuation in 25-hydroxyvitamin D was associated with increased levels of parathyroid hormone and C-terminal telopeptide.

Introduction

It is established that adequate 25-hydroxyvitamin D (25(OH)D, vitamin D) concentration is required for healthy bone mineralisation. It is unknown whether seasonal fluctuations in 25(OH)D also impact on bone health. If large seasonal fluctuations in 25(OH)D were associated with increased bone resorption, this would suggest a detriment to bone health. Therefore, this analysis assessed whether there is an association between seasonal variation in 25(OH)D and bone resorption.

Methods

The participants were (n?=?279) Caucasian and (n?=?88) South Asian women (mean (±SD); age 48.2 years (14.4)) who participated in the longitudinal Diet, Food Intake, Nutrition and Exposure to the Sun in Southern England study (2006–2007). The main outcomes were serum 25(OH)D, serum parathyroid hormone (sPTH) and serum C-terminal telopeptide of collagen (sCTX), sampled once per season for each participant.

Results

Non-linear mixed modelling showed the (amplitude/mesor) ratio for seasonal change in log 25(OH)D to be predictive of log sPTH (estimate?=?0.057, 95 % CI (0.051, 0.063), p?<?0.0001). Therefore, individuals with a higher seasonal change in log 25(OH)D, adjusted for overall log 25(OH)D concentration, showed increased levels of log sPTH. There was a corresponding significant ability to predict the range of seasonal change in log 25(OH)D through the level of sCTX. Here, the corresponding parameter statistics were estimate?=?0.528, 95 % CI (0.418, 0.638) and p?≤?0.0001.

Conclusions

These findings suggest a possible detriment to bone health via increased levels of sPTH and sCTX in individuals with a larger seasonal change in 25(OH)D concentration. Further larger cohort studies are required to further investigate these preliminary findings.     

孕妇血清25羟基维生素D水平与妊娠合并症的关系

维生素D是一种脂溶性类固醇激素,通过其循环活性形式25羟基维生素D(25OHD)在人体中发挥作用。维生素D可调节机体钙磷平衡,维持骨骼健康,对人体免疫调节、葡萄糖代谢、细胞增殖等生理过程均有重要作用。孕期女性血清25OHD的缺乏主要由于日照不足和摄入过少导致。25OHD的水平与妊娠合并症(如妊娠高血压、子痫前期和妊娠糖尿病)密切相关,25OHD的缺乏与妊娠高血压和子痫前期呈显著正相关,与妊娠糖尿病则呈负相关。本文就25OHD与妊娠合并症的关系进行综述。     

Non-linear relationship between serum 25-hydroxyvitamin D concentration and subsequent hip fracture

Summary

Serum 25-OH vitamin D levels were compared in 254 hip fracture subjects and 2,402 matched control subjects. There was a significant inverse association between 25-OH vitamin D and hip fracture only between 0 and 70 nmol/L.

Introduction

Vitamin D is integral to bone metabolism, however the utility of serum 25-OH vitamin D as a risk marker for hip fractures is controversial.

Methods

We conducted a case–control study of patients admitted to the hospitals with hip fractures in Calgary, Alberta, (catchment population 1.4 million) between January 1, 2007 and August 31, 2011. We searched the laboratory information system of Calgary Laboratory Services for serum 25-OH vitamin D levels within 6 months prior to admission on patients admitted to hospital with hip fractures. Cases were identified through the Calgary Laboratory Services laboratory information system and were matched to controls for age, sex, and month of testing. The hip fracture–25-OH vitamin D association was examined using multiple linear and spline regression.

Results

Of 305 subjects initially identified with hip fractures, serum 25-OH vitamin D levels were available for 254 (83 %). These were matched to 2,402 control subjects. We observed a significant (p?<?0.01) non-linear relationship such that 25-OH vitamin D was inversely associated with hip fracture only below 70 nmol/L (odds ratio?=?0.81 per 10 nmol/L increase; 95 % CI 0.86–0.93).

Conclusions

The utility of 25-OH vitamin D level as a risk marker for hip fracture depends on the cut-off level used and was of potential use only for lower levels of 25-OH vitamin D.     

Relationship between serum 25-hydroxyvitamin D3 and heart valvular calcification in chronic kidney disease patients stage 3-5

Objective To detect the prevalence of heart valvular calcification (VC) and its related risk factors, and to investigate correlation between serum 25-hydroxyvitamin D3[25(OH)D3] and VC in chronic kidney disease (CKD) stage 3-5 patients. Methods A total of 294 CKD patients stage 3-5 were admitted in The Second Affiliated Hospital of Anhui Medical University. Their clinical and laboratory data were collected, patients were classified into two groups according echocardiography: patients with VC were defined as VC group while others were defined as non-VC group. The differences of 25(OH)D3 level and other data in two group were assessed, and related risk factors of VC were analyzed. Results Among 294 CKD patients, 82 were with VC (27.9%) while 212 were without VC (72.1%); serum 25(OH)D3 level was significantly higher in VC group than in non-VC group [(11.9±9.3) μg/L vs (9.6±7.2) μg/L, P＜0.05]. Age, cystatin C, hypersensitive C-reactive protein, pulmonary artery pressure, proportion of secondary hyperparathyroidism, incidence of abdominal aortic calcification and taking active vitamin D proportion were higher in VC group than in non-VC group (P＜0.05). Two classification logistic regression analyses showed that advanced age, high intact parathyroid hormone (iPTH) and 25(OH)D3, pulmonary arterial hypertension were risk factors for VC in CKD stage 3-5 patients. Conclusions The prevalence of VC is high in CKD stage 3-5 patients. Advanced age, bone metabolic disorder and pulmonary arterial hypertension are associated with VC.     

未绝经女性甲亢患者血25羟维生素D水平与骨密度的关系

目的 观察未绝经女性甲亢患者骨密度及血钙、血磷、血碱性磷酸酶（ALP）、血浆25羟维生素D[25(OH)D]、血浆甲状旁腺激素（PTH）水平变化,分析未绝经女性甲亢患者血浆25(OH)D与骨密度的关系。方法 选取50例初发或复发的未绝经女性甲亢患者,51例正常对照人群,应用双能X线吸收仪（DXA）测定腰椎1-4、股骨颈、股骨大转子、Ward三角和全股骨的骨密度,电化学发光法测定血浆25(OH)D和PTH,生化法测定血钙、磷、ALP。结果 甲亢组L1、Ward三角骨密度均低于对照组,差异有统计学意义。与对照组相比,甲亢组血钙、血ALP、血浆25(OH)D水平升高,血浆PTH降低,差异均有统计学意义。甲亢组维生素D缺乏17例(34%) , 不足19例(38%) , 充足14例(28%)。对照组维生素D缺乏30例(59%) , 不足18例(35%), 充足3例(6%)。相关分析示,两组血浆25（OH）D与L1、L2、L3、L4、L1-4、股骨颈、股骨大转子、Ward三角、全股骨骨密度均无相关性。Pearson相关分析示,甲亢组血浆25(OH)D与PTH呈负相关（r=-0.378,P<0.01）。结论 未绝经女性甲亢患者L1、Ward三角骨密度降低。未绝经女性甲亢患者血浆25(OH)D升高,可能与高血钙、PTH分泌抑制、高血磷导致1-α-羟化酶活性降低有关。未绝经女性甲亢患者血浆25(OH)D水平与骨密度无直接关系。     

25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy

BACKGROUND: The importance of 25-hydroxyvitamin D (25-OHD) serum levels in hemodialysis chronic renal failure has not been so far histologically evaluated. Information still lacking relate to the effect of 25-OHD deficiency on serum parathyroid hormone (PTH) levels and on bone and its relationship with calcitriol levels. METHODS: This retrospective study has been performed on a cohort of 104 patients on hemodialysis from more than 12 months, subjected to transiliac bone biopsy for histologic, histomorphometric, and histodynamic evaluation. The patients, 61 males and 43 females, mean age 52.9 +/- 11.7 years, hemodialysis length 97.4 +/- 61.4 months, were treated with standard hemodialysis and did not receive any vitamin D supplementation. Treatment with calcitriol was not underway at the time of the biopsy. Transiliac bone biopsies were performed after double tetracycline labels. In addition, serum intact PTH (iPTH), alkaline phosphatase, and 25-OHD were measured. Calcitriol serum levels was also measured in a subset of patients (N= 53). The patients were divided according to serum 25-OHD levels in three groups: (1) 0 to 15 (15 patients), (2) 15 to 30 (38 patients), and (3) >30 ng/mL (51 patients). RESULTS: There was no significant difference in average age, hemodialysis age, serum PTH [490 +/- 494, 670 +/- 627, and 489 +/- 436 pg/mL, respectively (mean +/- SD)], alkaline phosphatase, and calcitriol between the three groups. The parameters double-labeled surface, trabecular mineralizing surface, and bone formation rate were significantly lower in group 1 than in the other groups (P < 0.03, < 0.03, and < 0.02, respectively). Osteoblast surface and adjusted apposition rate were borderline significantly lower in group 1 (P < 0.06 and < 0.10). There was no statistical difference in the biochemical and bone parameters between groups 2 and 3. A positive significant correlation was found between several bone static and dynamic parameters and 25-OHD levels in the range 0 to 30 ng/mL, showing a vitamin D dependence of bone turnover at these serum levels. However, actual evidence of an effect on bone of 25-OHD deficiency was found at serum levels below 20 ng/mL. With increasing 25-OHD levels beyond 40 ng/mL, a downslope of parameters of bone turnover was also observed. CONCLUSION: Since PTH serum levels are equally elevated in low and high 25-OHD patients, while calcitriol levels are constantly low, an effect of 25-OHD deficiency (group 1) on bone, consisting of a mineralization and bone formation defect, can be hypothesized. The effect of vitamin D deficiency or bone turnover is found below 20 ng/mL. The optimal level of 25-OHD appears to be in the order of 20 to 40 ng/mL. Levels of the D metabolite higher than 40 ng/mL are accompanied by a reduction of bone turnover.     

Predictors and relationships of serum 25 hydroxyvitamin D concentration with bone turnover markers, bone mineral density, and vitamin D receptor genotype in Emirati women

OBJECTIVES: To determine factors influencing serum 25 hydroxyvitamin D (25OHD) concentration and relationships between serum 25OHD concentration, bone turnover markers, bone mineral density (BMD), and vitamin D receptor (VDR) genotype in Emirati women. METHODS: Serum 25OHD, parathyroid hormone (PTH), osteocalcin (OC), vitamin D binding protein (VDBP), and urinary deoxypyrdinoline (UDPD) concentrations and VDR genotype were determined in Emirati women volunteers who were participating in a study aiming at establishing a reference database for BMD. RESULTS: Serum 25OHD concentration in the 259 women volunteers was 25.3 +/- 10.8 nmol/l (mean +/- SD), and all had vitamin D deficiency (25OHD <80 nmol/l). Mean serum 25OHD was highest in April (29.2 +/- 13.0 nmol/l), which marks the end of the short and cooler winter season, and lowest in August (18.2 +/- 5.9 nmol/l). No significant difference in 25OHD concentration was noted among Emirati women wearing different dress styles, but the mean serum 25OHD was significantly lower in comparison with non-Arab Caucasian women volunteers who dressed in a Western style (P < 0.001). Serum 25OHD correlated positively with age (r = 0.2), number of pregnancies (r = 0.16), dietary vitamin D intake (r = 0.15), serum calcium (r = 0.14), phosphorus (r = 0.14), VDBP (r = 0.15), and urinary calcium/creatinine (r = 0.2), and inversely with PTH (r = -0.22), OC (r = -0.13), and UDPD/creatinine (r = -0.15); P < 0.05 for all correlations. Multiple linear regression analysis showed that age, dietary vitamin D intake, multivitamin intake, and cooler season were independent positive predictors of serum 25OHD concentration (R(2) = 0.18). The frequencies of VDR genotypes were 36% GG, 44.1% AG, and 19.9% AA. Allele frequencies were 58% for G allele and 42% for A allele and were in Hardy-Weinberg equilibrium (x(2) = 1.44; P > 0.1). There was no statistically significant influence of VDR genotype on bone turnover or BMD. CONCLUSIONS: Vitamin D deficiency is highly prevalent in Emirati women and appears largely attributable to insufficient sunlight exposure. It is associated with increased bone turnover. VDR genotype does not appear to influence bone turnover markers or BMD in Emirati women.     

The role of vitamin D metabolites in bone resorption

Two metabolites of vitamin D₃, 25-hydroxycholecalciferol (25-OHD₃) and 1,25-dihydroxy-cholecalciferol (1,25-(OH)₂D₃) are potent stimulators of bone resorption in two test systems whereas vitamin D₃ itself is inactive. These substances were tested (a) by directly comparing their action on bone explants of mouse half-calvariain vitro, and (b) by injecting them into young mice and measuring the degree of resorptionin vitro when explants were made 18 hours atter the injection. In both tests the 1,25-metabolite was about 100 times more potent than 25-OHD₃. The dose-response curve for 1,25-(OH)₂D₃ indicates that doses above about 0.2 ng/g body weight are capable of inducing an increase in bone resorption in normal young mice. These data show that 1,25-(OH)₂D₃ is one of the most potent substances known that affects bone metabolism. The results are discussed in relation to the possible role of 1,25-(OH)₂D₃ in the normal mobilization of calcium from bone.

---

Zusammenfassung Bei Anwendung zweier verschiedener Versuchsanordnungen konnte gezeigt werden, daß die beiden Vitamin D₃-Metaboliten 25-Hydroxycholecalciferol (25-OHD₃) und 1,25-Dihydroxycholecalciferol (1,25-(OH)₂D₃) als starke Stimulatoren der Knochenresorption wirken, während sich Vitamin D₃ selbst inaktiv verhält. Diese Substanzen wurden folgendermaßen geprüft: a) durch direkten Vergleich ihrer Wirkung auf Knochenexplantate (Hälften von Mäusecalvarien)in vitro und b) indem die Metaboliten jungen Mäusen injiziert wurden und der Resorptionsgrad an Explantaten 18 Std nach Injektionin vitro gemessen wurde. Bei beiden Versuchsanordnungen war der 1,25-Metabolit etwa 100mal wirksamer als der 25-OHD₃-Metabolit. Aus der Dosiswirkungskurve für 1,25-(OH)₂D₃ geht hervor, daß es möglich ist, mit Dosen über ca. 0,2 ng/g Körpergewicht bei normalen jungen Mäusen bereits eine erhöhte Knochenresorption auszulösen. Diese Resultate zeigen, daß 1,25-(OH)₂D₃ eine der wirksamsten bisher bekannten Substanzen ist, die auf den Knochenmetabolismus einwirken können. Die Ergebnisse werden im Zusammenhang mit der Rolle, die das 1,25-(OH)₂D₃ bei der normalen Freisetzung von Calcium aus dem Knochen spielt, besprochen.

---

Résumé Deux métabolites de la vitamine D₃, le 25-hydroxycholecalciferol (25-OHD₃) et 1,25-dihydroxycholecalciferol (1,25-(OH)₂D₃), stimulent la résorption osseuse dans deux systèmestests alors que la vitamine D₃ est inactive. Ces substances sont testées a) en comparant directement leur action dans les explants osseux de calottes craniennes de sourisin vitro et b) en les injectant dans de jeunes souris et en mesurant le degré de résorptionin vitro, lorsque les explants sont réalisés 18 heures après l'injection. Dans les deux tests, le métabolite 1,25 est environ 100 fois plus puissant que 25-OHD₃. La courbe dose-résponse de 1,25-(OH)₂D₃ indique que des doses au-dessus d'environ 0.2 ng/g de poids corporel sont capables d'induire une augmentation de la résorption osseuse chez de jeunes souris normales. Ces résultats montrent que 1,25-(OH)₂D₃ est une des substances connues les plus actives qui agit sur le métabolisme osseux. Le rôle possible de 1,25-(OH)₂D₃ sur la mobilisation normale du calcium osseux est envisagé.

     

青年男性血清25羟维生素D、PTH水平与区域骨密度的关系

目的 调查广州地区青年男性维生素D、PTH状态及其与区域骨密度之间的关系.方法 随机选取2011年5月-2012年8月在广州军区广州总医院门诊部体检的60名广州青年男性志愿受试者,年龄18～44岁.评估血清25(OH)D、PTH水平,并分析血清25(OH)D、PTH与骨转换指标和区域骨密度(BMD)的相关性.结果 46.7％的青年男性血清25(OH)D水平＞30 ng/mL,53.3％低于30 ng/mL,5％低于20 ng/mL.血清25(OH)D水平与年龄分布无统计学差异(P＞0.05).双变量分析显示血清25(OH)D水平与PTH负相关(r=-0.264,P=0.042),与β-Crosslaps负相关(r=-0.257,P=0.047).血清25(OH)D水平、PTH与L1-4以及单个腰椎L1、L2、L3、L4的BMD无相关性.股骨大转子BMD与血清25(OH)D正相关(r=0.271,P=0.040),校正年龄、BMI和骨生化指标后,正相关性更加明显(r =0.319,P=0.020).多元线性回归分析显示BMI、ALP与全腰、L1、L3、L4椎BMD相关,BMI、PINP与L2椎BMD相关,BMI、25(OH)D与全髋、大转子BMD相关.结论 青年男性广泛存在血清25(OH)D不足状态,血清25(OH)D水平与股骨大转子BMD明显正相关,适当补充维生素D和钙剂,对维持大转子区域的骨量至关重要.     

50 -60岁绝经后骨折女性25(OH)D3和骨密度、骨代谢指标的关系研究

目的探讨50-60岁绝经后骨折女性25羟维生素D_3和骨密度、骨代谢指标的关系。方法选择2014年7月至2015年9月因骨折在我院骨科行手术治疗的50-60岁绝经后女性90例,检测患者腰椎和股骨近端部位骨密度并分为骨质疏松组、骨量减少组及骨量正常组。检测患者身高、体重及25羟维生素D_3、骨碱性磷酸酶、骨钙素、I型胶原羧基末端肽、I型原胶原羧基末端肽及尿Ⅰ型胶原氨基末端肽等骨代谢指标。结果血清25羟维生素D_3水平随着骨密度降低而降低(P0.05);血清骨碱性磷酸酶、骨钙素、I型胶原羧基末端肽、I型原胶原羧基末端肽及尿I型胶原氨基末端肽水平随着血清25羟维生素D_3水平降低而升高(P0.05);血清25羟维生素D_3水平随着年龄增加而降低(P0.05)。结论在50-60岁绝经后女性骨折患者中,血清25羟维生素D_3水平与骨密度存在正性相关关系;血清25羟维生素D_3与血清骨碱性磷酸酶、骨钙素、I型胶原羧基末端肽、I型原胶原羧基末端肽及尿I型胶原氨基末端肽水平存在负性相关关系。50-60岁绝经后女性应及时补充维生素D,并随着绝经年限的增加而适当增加,可以增加骨量,从而可能减少各种并发症的发生。     

老年女性血清25-羟基维生素D的独立相关因素

目的通过筛选老年女性血清25-羟基维生素D[25(OH)D]的独立相关因素,寻找提高老年女性血清25(OH)D的方法。方法对280例老年女性进行伴随疾病和生活方式的调查,并进行骨代谢、血液生化、性激素和贫血等指标的检测,运用多元回归分析方法筛选老年女性血清25(OH)D的独立相关因素。结果老年女性血清25(OH)D的独立相关因素包括血PTH(β=-0.097,P0.01)、血磷(β=-18.144,P0.01)、血钙(β=19.912,P0.01)、服用复方钙剂(β=5.362,P0.01)和晒太阳(β=0.974,P0.05)。结论坚持晒太阳、服用复方钙剂和补充维生素D,可能是提高老年女性血清25(OH)D水平的重要方法。     

Serum 25-hydroxyvitamin D and bone mineral density among Hispanic men

Summary  There are few data on the skeletal health of Hispanic men. We observed differences in vitamin D deficiency and low BMD between Hispanic ethnic subgroups that persisted with adjustment for risk factors. Our data indicate a substantial burden of low BMD and vitamin D deficiency among Hispanic men. Introduction  Disparities within ethnic groups are generally ignored, but in evolving populations they may have implications for public health. We examined ethnic variation in serum 25-hydroxyvitamin D [25(OH)D] and bone mineral density (BMD) among Hispanic American men. Methods  Three hundred and fifty-eight Hispanic males 30 to 79 years of age were studied. Logistic regression models assessed variation in odds of vitamin D deficiency (<20 ng/mL) and low BMD (T-score<−1) by ethnicity, with and without adjustment for risk factors (age, smoking, occupation, physical activity, body mass index, and sunlight exposure). Results  Vitamin D deficiency was most common among Puerto Rican (26%), compared with Dominican (21%), Central American (11%), and South American (9%) men. Percentages with low BMD were: South American (44%), Puerto Rican (34%), Dominican (29%), and Central American (23%). Adjustment for age and risk factors failed to account for Hispanic subgroup differences in vitamin D deficiency and low BMD. Population estimates indicate a substantial burden of low BMD and vitamin D deficiency among Hispanic men. Conclusions  Our findings underscore the importance of examining the skeletal health of Hispanic subgroups, and suggest that a considerable number of Hispanic men may be at elevated risk of fracture and vitamin D deficiency. Grant Support: The BACH/Bone Survey was supported by grant AG 20727 from the National Institute on Aging (NIA). The parent study (BACH) was supported by grant DK 56842 from the National Institute of Diabetes and Digestive and Kidney Diseases. Additional support from MO RR00533.